

12-01-03

16:22

From-CLARK & ELBING LLP

+6174287045

T-665 P.001/004 F-711

OFFICIAL

RECEIVED
CENTRAL FAX CENTER

DEC 01 2003

Clark & Elbing LLP

101 Federal Street
Boston, MA 02110

Telephone 617-428-0200
Facsimile 617-428-7045
617-428-7046

Date: December 1, 2003

To: Examiner Shin Lin Chen
United States Patent and Trademark Office
Art Unit1632

Facsimile No: 1-703-872-9306

From: Kristina Bieker-Brady, Ph.D.
Reg. No: 39,109

Re: H. Robert Horvitz et al.
09/993,420
November 6, 2001
IDENTIFICATION AND CHARACTERIZATION OF A
GENE WHICH PROTECTS CELLS FROM PROGRAMMED
CELL DEATH AND USES THEREFOR

Pages: 4, Including Fax Cover Sheet


Message: Attachment:

Terminal Disclaimer

3 Pages

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

PATENT
ATTORNEY DOCKET NO.: 01997/201006

| | |
|--|--|
| Certificate of Facsimile | |
| Date of Transmission: <u>December 1, 2003</u> | |
| I hereby certify under 37 C.F.R. 1.8(a) that this correspondence is being facsimile transmitted to the Patent and Trademark Office on the date indicated above. ATTN: Examiner Shin Lin Chen, Fax 1-800-872-9306 | |
| Guy F. Beardsley |  |
| Printed Name of Person Transmitting Facsimile | Signature of Person Transmitting Facsimile |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: H. Robert Horvitz et al. Art Unit: 1632
Serial No.: 09/993,420 Examiner: Shin Lin Chen
Filed: November 6, 2001 Customer No.: 21559
Title: IDENTIFICATION AND CHARACTERIZATION OF A GENE
WHICH PROTECTS CELLS FROM PROGRAMMED CELL DEATH
AND USES THEREFOR

RECEIVED
CENTRAL FAX CENTER

DEC 01 2003

OFFICIAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. §§ 1.321 and 3.73(b)

Pursuant to 37 C.F.R. § 1.321(b), the Massachusetts Institute of Technology, the assignee of the entire right, title, and interest in the above-captioned application, seeks to disclaim the terminal portion of the term of the patent to be granted on the application. This terminal disclaimer is binding on the grantee and its successors or assigns.

Pursuant to 37 C.F.R. § 1.321(b)(1), this terminal disclaimer is signed by an attorney of record.

Pursuant to 37 C.F.R. § 1.321(b)(2), the Massachusetts Institute of Technology hereby waives and disclaims the terminal portion of the term of the entire patent to be

granted upon the application subsequent to the expiration date of U.S. Patent No. 6,312,947. The Massachusetts Institute of Technology does not disclaim any terminal part of any patent granted on the application prior to the expiration date of the full statutory term of U.S. Patent No. 6,312,947 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.

Pursuant to 37 C.F.R. § 1.321(b)(3) and § 3.73(b), the undersigned attorney of record certifies that the Massachusetts Institute of Technology, a university, is the assignee of the entire right, title, and interest in the application by virtue of an assignment from the inventors of the application. The assignment was recorded in the Patent and Trademark Office at Reel/Frame 014122/0033 on November 13, 2003.

The undersigned attorney/agent of record has reviewed all the documents in the chain of title of the application and to the best of the undersigned's knowledge and belief, title is in the name of the Massachusetts Institute of Technology.

Pursuant to 37 C.F.R. § 1.321(b)(4), please charge \$110.00 for the fee set forth in 37 C.F.R. § 1.20(d) to Deposit Account Number 03-2095.

Further, pursuant to 37 C.F.R. § 1.321(c)(3), this terminal disclaimer is being filed to overcome a double patenting rejection in the application. Any patent granted on the


application or any resulting patent subject to reexamination proceedings shall be enforceable only for and during such period that the patent is commonly owned with the application or patent that formed the basis for the rejection.

If there are any additional charges or any credits, please apply them to Deposit Account Number 03-2095.

Respectfully submitted,

Date:

December 1, 2003



Kristina Bieker-Brady, Ph.D.

Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045
01997.201006 Terminal Disclaimer.doc